E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention or attenuation of COPD symptoms caused by respiratory viruses |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This is a Phase II study in which we are trying to see if SNG001 is better than placebo at controlling COPD symptoms during common cold infections. SNG001 is given by a nebulizer, and the solution contains interferon-β, which is an antiviral protein (which we all have). We believe there is a deficiency of this protein in COPD patients when respiratory viruses are present. This may explain why COPD patients suffer an exacerbation (deterioration) of their symptoms when they get a cold (or flu). We will test the drug by looking to see if their COPD symptom (EXACT-Pro) peak score is lower in the SNG001 treated subjects compared to the placebo treated group between day 3 and day 14. The COPD score is a score calculated daily and consists of questions regarding the subjects COPD symptoms.
We will have 83 subjects in each group. This has been calculated to be enough subjects to make a meaningful statistical comparison.
|
|
E.2.2 | Secondary objectives of the trial |
This is the first time that a drug like SNG001 has been used to treat COPD subjects during common cold infections. As such the research team (led by experienced statisticians) will analyse data from a variety of other measurements made during the study. These will be:
a) The same as the primary objective but looking at the per protocol population rather than the modified intention to treat population. b) To look at the EXACT-PRO scores in a number of different ways; specifically the peak score between days 3 and 28; to see if the area under the curve is lower in the SNG001 treated subjects compared to the placebo treated group between day 3 and day 7 and day 3 and day 28; and to look at the peak rolling day average between days 3 and 7 and days 3 and 28. c) To look at the effect of inhaled SNG001 to placebo on FEV1 between day 1 and 28. d) To compare the effect of inhaled SNG001 to placebo on the reduction of viral load on days 4 and 7 in sputum. e) To compare the effec |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1)Male or female, over 40 years of age. 2)A confirmed diagnosis of COPD or a medical history consistent with a diagnosis of COPD. 3)FEV1 > 20% of predicted and < 70% of predicted post-bronchodilator, on the day of screening. 4)To have had at least one COPD exacerbation suspected to have been caused by a respiratory virus in the last 24 months requiring intervention with oral steroids or antibiotics. 5)Has experienced respiratory virus symptoms that have developed within the previous 48 hours, but preferably 24 hours, specifically a blocked or runny nose, and a sore or scratchy throat. 6)Provide written informed consent. 7)Females of child-bearing potential must be using a medically acceptable and adequate form of birth control and agree to maintain this usage throughout the duration of the study. 8)Motivation (in the Investigator’s opinion) to complete all study visits and assessments, the ability to communicate well with the Investigator and be capable of understanding the nature of the research and its treatment, including its risks and benefits.
|
|
E.4 | Principal exclusion criteria |
1)Any condition, including findings in the medical history that, in the opinion of the Investigator, constitutes a risk or a contraindication for the participation of the subject in the study or that could interfere with the study objectives, conduct or evaluation. 2)Patients who have a current moderate or severe exacerbation of COPD. 3)Oxygen saturation of less than 92% (taken on air, unless the subject is routinely prescribed oxygen when they are stable). 4)Current participation in an interventional trial. 5)Patients who have received a dose of a test product (IMP) within 12 weeks prior to entry into the study for small molecules and within 6 months prior to entry into the study for biologicals. 6)Patients who have had a COPD exacerbation and/or upper or lower respiratory tract infection that resolved less than 4 weeks ago. 7)Patients who are currently taking, or have taken oral steroids or antibiotics within the last four weeks. 8)Active interstitial lung disease or past history of lung cancer not considered cured, significant bronchiectasis, cystic fibrosis or a history of significant chronic asthma. 9)Patients with serious underlying medical conditions that could impact interpretation of results should be excluded (e.g. infection, haematological disease, malignancy, renal, hepatic, coronary heart disease or other cardiovascular disease, including arrhythmias, endocrinological or gastrointestinal disease). 10)History of hypersensitivity to natural or recombinant IFN-β or to any of the drug preparation excipients. 11)Patients with current severe depression and/or suicidal ideation. 12)History of epilepsy or seizures after the age of 5 years. 13)Recent history of drug or alcohol abuse. 14)Female who is breast-feeding, pregnant or intends to become pregnant. 15)Patients who require more than 12 hours’ oxygen therapy per day. 16)Patients who are currently in a pulmonary rehabilitation programme. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the peak EXACT-PRO score observed between days 3 and 14 in the mITT population. Days are defined with respect to day 1 being Visit 1 which occurs within 48 hours of the onset of cold symptoms and is the day of first dose.
The primary objective will be assessed by testing the following null hypothesis:
H0: There is no difference in the peak EXACT-PRO score observed between days 3 and 14 for inhaled SNG001 compared to placebo in the mITT population
versus the two-sided alternative hypothesis:
H1: There is a difference in the peak EXACT-PRO score observed between days 3 and 14 for inhaled SNG001 compared to placebo in the mITT population.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
compare frequency of use of concomitant medications |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 0 |